Martin Balslev Jørgensen

Martin Balslev Jørgensen

Auto-generated profile, based on publicly available information

Martin Balslev Jørgensen

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1982 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MJMartin Balslev Jørgensen
Martin Balslev Jørgensen
NDNils Henrik Diemer
Nils Henrik Diemer
Male Wistar rats were subjected to 20 min of cerebral ischemia by means of 4-vessel occlusion. The topography of regional, selective neuron loss in this model corresponded to areas with pronounced glutamate high affinity uptake (presynaptic receptors), suggesting that transmitter glutamate is involved in the mechanism of neuron damage. One group of animals was injected with the glutamate antagonist, glutamic acid diethyl ester (GDEE) before ischemia. The regional neuron loss was rated using a semiquantitative scale. No statistically significant difference was found between the groups. The results do not exclude a possible role of transmitter glutamate in the pathogenesis of ischemic brain damage. More specific and potent glutamate antagonists are needed in order to clarify such a mechanism.

1 October 1989 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
HBH. Benveniste
H. Benveniste
MJM. B. Jørgensen
M. B. Jørgensen
MSM. Sandberg
M. Sandberg
TCT. Christensen
T. Christensen
HHHenrik Hagberg
Henrik Hagberg
NDN. H. Diemer
N. H. Diemer
The removal of glutamatergic afferents to CA1 by destruction of the CA3 region is known to protect CA1 pyramidal cells against 10 min of transient global ischemia. To investigate further the pathogenetic significance of glutamate, we measured the release of glutamate in intact and CA3-lesioned CA1 hippocampal tissue. In intact CA1 hippocampal tissue, glutamate increased sixfold during ischemia; in the CA3-lesioned CA1 region, however, glutamate only increased 1.4-fold during ischemia. To assess the neurotoxic potential of the ischemia-induced release of glutamate, we injected the same concentration of glutamate into the CA1 region as is released during ischemia in normal, CA3-lesioned, and ischemic CA1 tissue. We found that this particular concentration of glutamate was sufficient to destroy CA1 pyramids in the vicinity of the injection site in intact and CA3-lesioned CA1 tissue when administered during control (non-ischemic) conditions. In contrast, the same amount injected during ischemia in the CA3-lesioned CA1 region destroyed pyramidal cells in a widely distributed zone around the injection site in the CA1 region. It is concluded that the ischemia-induced damage of pyramidal cells in CA1 is dependent on glutamate release and intact innervation from CA3.

1 March 1993 in Experimental Neurology
Verified
Journal Article
Closed access
MJMartin B. Jørgensen
Martin B. Jørgensen
BFBente Finsen
Bente Finsen
MJMichael B. Jensen
Michael B. Jensen
BCBernardo Castellano
Bernardo Castellano
NDNils H. Diemer
Nils H. Diemer
JZJens Zimmer
Jens Zimmer

1 October 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
TJTerese S. H. Jørgensen
Terese S. H. Jørgensen
IWIda K. Wium-Andersen
Ida K. Wium-Andersen
MWMarie K. Wium-Andersen
Marie K. Wium-Andersen
MJMartin B. Jørgensen
Martin B. Jørgensen
EPEva Prescott
Eva Prescott
MOMerete Osler
Merete Osler
In 2013, more than 10 million people had a stroke, and in excess of 30 million people lived with a stroke diagnosis worldwide.1 Depression is common after stroke, and studies2-13 have evaluated its frequency, risk factors, and mortality. However, recent systematic reviews2-4,9,13 of more than 50 cohorts have been hampered by heterogeneity across studies and small sample sizes; consequently, the reported frequency of depression after stroke has varied from 2% to 55% in population-based cohorts,2-4,13 with pooled estimates between 29% and 31% in recent meta-analyses.3,4 Only 2 studies5,6 (with sample sizes <300) examining the risk of depression after stroke included a reference population selected from the community, and they indicated that, although depression is more common after stroke than in control individuals, the differences were not substantial and had largely disappeared after 1 year.

1 November 1982 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MLMartin Lauritzen
Martin Lauritzen
MJMartin Balslev Jøsrgensen
Martin Balslev Jøsrgensen
NDNiels Henrik Diemer
Niels Henrik Diemer
Albert GjeddeAlbert Gjedde
Albert Gjedde
AHAnker Jóan Hansen
Anker Jóan Hansen

1 October 2018 in Biological Psychiatry
Verified
Journal Article
Open access
LOLeif Oltedal
Leif Oltedal
KNKatherine L. Narr
Katherine L. Narr
CAChristopher Abbott
Christopher Abbott
AAAmit Anand
Amit Anand
MAMiklos Argyelan
Miklos Argyelan
ADAnders M. Dale
Anders M. Dale
Hippocampal enlargements are commonly reported after electroconvulsive therapy (ECT). To clarify mechanisms, we examined if ECT-induced hippocampal volume change relates to dose (number of ECT sessions and electrode placement) and acts as a biomarker of clinical outcome. Longitudinal neuroimaging and clinical data from 10 independent sites participating in the Global ECT-Magnetic Resonance Imaging Research Collaboration (GEMRIC) were obtained for mega-analysis. Hippocampal volumes were extracted from structural magnetic resonance images, acquired before and after patients (n = 281) experiencing a major depressive episode completed an ECT treatment series using right unilateral and bilateral stimulation. Untreated nondepressed control subjects (n = 95) were scanned twice. The linear component of hippocampal volume change was 0.28% (SE 0.08) per ECT session (p < .001). Volume change varied by electrode placement in the left hippocampus (bilateral, 3.3 ± 2.2%, d = 1.5; right unilateral, 1.6 ± 2.1%, d = 0.8; p < .0001) but not the right hippocampus (bilateral, 3.0 ± 1.7%, d = 1.8; right unilateral, 2.7 ± 2.0%, d = 1.4; p = .36). Volume change for electrode placement per ECT session varied similarly by hemisphere. Individuals with greater treatment-related volume increases had poorer outcomes (Montgomery-Åsberg Depression Rating Scale change -1.0 [SE 0.35], per 1% volume increase, p = .005), although the effects were not significant after controlling for ECT number (slope -0.69 [SE 0.38], p = .069). The number of ECT sessions and electrode placement impacts the extent and laterality of hippocampal enlargement, but volume change is not positively associated with clinical outcome. The results suggest that the high efficacy of ECT is not explained by hippocampal enlargement, which alone might not serve as a viable biomarker for treatment outcome.